Search results
Results From The WOW.Com Content Network
People diagnosed with ALS live on average 2–4 years after diagnosis due to the quick progression of the disease. [2] [3] The progression and severity of ALS is rated by doctors on the ALS Functional Rating Scale, which has been revised and is referred to as ALSFRS-R.
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file.
ALS is the most common form of the motor neuron diseases. [8] ALS often presents in its early stages with gradual muscle stiffness, twitches, weakness, and wasting. [3] Motor neuron loss typically continues until the abilities to eat, speak, move, and, lastly, breathe are all lost. [3]
Acrobat Reader Touch is a free PDF document viewer developed and released on December 11, 2012, by Adobe Systems for the Windows Touch user interface. FormsCentral was a web form filling server for users with Windows, macOS, or a web browser and an Adobe ID only.
Articles relating to amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease. It is a specific disease which causes the death of neurons controlling voluntary muscles. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size.
In the Print/export section select Download as PDF. The rendering engine starts and a dialog appears to show the rendering progress. When rendering is complete, the dialog shows "The document file has been generated. Download the file to your computer." Click the download link to open the PDF in your selected PDF viewer.
The following diagnostic systems and rating scales are used in psychiatry and clinical psychology. This list is by no means exhaustive or complete. This list is by no means exhaustive or complete. For instance, in the category of depression, there are over two dozen depression rating scales that have been developed in the past eighty years.
The institute has raised and spent more than $100 million on research into effective treatments for ALS and practices open-source science. [19] After the discovery that the multiple sclerosis drug Gilenya might also be a treatment for ALS, the Institute enrolled 30 people in a Phase 2A clinical trial the drug in 2013, though it did not progress further.